U.S. markets closed
  • S&P 500

    4,544.90
    -4.88 (-0.11%)
     
  • Dow 30

    35,677.02
    +73.94 (+0.21%)
     
  • Nasdaq

    15,090.20
    -125.50 (-0.82%)
     
  • Russell 2000

    2,291.27
    -4.92 (-0.21%)
     
  • Crude Oil

    83.98
    +1.48 (+1.79%)
     
  • Gold

    1,793.10
    +11.20 (+0.63%)
     
  • Silver

    24.39
    +0.22 (+0.91%)
     
  • EUR/USD

    1.1646
    +0.0015 (+0.13%)
     
  • 10-Yr Bond

    1.6550
    -0.0210 (-1.25%)
     
  • GBP/USD

    1.3760
    -0.0036 (-0.26%)
     
  • USD/JPY

    113.4800
    -0.5080 (-0.45%)
     
  • BTC-USD

    61,469.64
    -1,770.63 (-2.80%)
     
  • CMC Crypto 200

    1,453.34
    -49.69 (-3.31%)
     
  • FTSE 100

    7,204.55
    +14.25 (+0.20%)
     
  • Nikkei 225

    28,804.85
    +96.27 (+0.34%)
     

ALX Oncology Shares Jump As ALX148 Shows ORR of 72% In Patients With HER2 Positive Stomach Cancer

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • ALX Oncology Holdings Inc (NASDAQ: ALXO) announced updated data from its ongoing ASPEN-01 Phase 1b trial evaluating ALX148 in combination with trastuzumab and chemotherapy to treat gastric or gastroesophageal junction cancer (GC).

  • The new data were shared at the World Congress on Gastrointestinal Cancer.

  • Data showed that ALX148, combined with trastuzumab and chemotherapy, is highly active and well-tolerated in patients with second-line or greater HER2 positive GC.

  • As of the data cut-off of May 3, 2021, ALX148 demonstrated a favorable initial confirmed objective response rate (ORR) of 72% and estimated overall survival (OS) at 12 months of 76%.

  • These results compare favorably to randomized historical control studies; RAINBOW reported an ORR of 28% and OS at 12 months of 40%, and DESTINY-01 reported an ORR of 41% and OS at 12 months of 52%.

  • Preliminary data suggest that ALX148 can be combined with trastuzumab, ramucirumab, and paclitaxel with no maximum tolerated dose reached.

  • The maximum administered dose of ALX148 in combination was 15 mg/kg once weekly.

  • ALX Oncology will host a conference call today at 8:30 a.m. E.T.

  • Price Action: ALXO shares are up 19.9% at $67 during the premarket session on the last check Tuesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.